Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to share pricing for specific transactions:
- Ordinary Share Price: 1454 pence
- American Depositary Share (ADS) Price: $47.463
Material Changes
The filing details increases in shareholdings for three individuals following the re-investment of dividends paid on October 4, 2012. These transactions include both personal contributions and company matching contributions under the Deferred Annual Bonus Plan:
- Mrs D P Connelly: Acquired 22.859 ADSs (personal) and 23.410 ADSs (company match).
- Mr M Dunoyer: Acquired 34.000 Ordinary Shares (personal) and 35.167 Ordinary Shares (company match).
- Mr W C Louv: Acquired 24.302 ADSs (personal) and 24.824 ADSs (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that notional dividends accrued under the matching element will be paid out based on vesting percentages after a three-year measurement period.
Investor Verification Checklist
- Verify the vesting schedule and conditions for the 2010 and 2011 deferred bonus awards mentioned.
- Confirm the total number of shares held by the named directors post-transaction.
- Review the full terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan to understand the matching contribution mechanics.